These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

556 related items for PubMed ID: 16191276

  • 1. [Matrix metalloproteinase-1 expression in the circulation of patients with Kawasaki disease and its role in the pathogenesis of coronary artery lesions].
    Yang SW, Wang DW, Li J, Qin YM, Wang FM, Cao LM, Zhang LF, Hu Z.
    Zhonghua Er Ke Za Zhi; 2005 Aug; 43(8):612-5. PubMed ID: 16191276
    [Abstract] [Full Text] [Related]

  • 2. [Clinical value of serum matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 for the prediction and early diagnosis of coronary artery lesion in patients with Kawasaki disease].
    Peng Q, Zhou TF, Chen CH, Hua YM, Liu HM, Hong H, Zhang LY, Wu Q.
    Zhonghua Er Ke Za Zhi; 2005 Sep; 43(9):676-80. PubMed ID: 16191301
    [Abstract] [Full Text] [Related]

  • 3. [Changes of P-selectin and E-selectin in children with Kawasaki disease].
    Qiu Y, Wu J, Fang XY, Lin Z, Wu BY, Cai RY, Xu XY, Zheng H.
    Zhonghua Er Ke Za Zhi; 2004 Sep; 42(9):688-92. PubMed ID: 15482673
    [Abstract] [Full Text] [Related]

  • 4. Elevated serum levels of matrix metalloproteinase-9 (MMP-9) in Kawasaki disease.
    Takeshita S, Tokutomi T, Kawase H, Nakatani K, Tsujimoto H, Kawamura Y, Sekine I.
    Clin Exp Immunol; 2001 Aug; 125(2):340-4. PubMed ID: 11529928
    [Abstract] [Full Text] [Related]

  • 5. Systemic arterial expression of matrix metalloproteinases 2 and 9 in acute Kawasaki disease.
    Gavin PJ, Crawford SE, Shulman ST, Garcia FL, Rowley AH.
    Arterioscler Thromb Vasc Biol; 2003 Apr 01; 23(4):576-81. PubMed ID: 12692003
    [Abstract] [Full Text] [Related]

  • 6. [Changes and significance for regulatory factors for signal pathways of Toll-like receptors in immunological pathogenesis of Kawasaki disease].
    Wang GB, Li CR, Zu Y, Yang WG.
    Zhonghua Er Ke Za Zhi; 2008 Jan 01; 46(1):49-54. PubMed ID: 18353240
    [Abstract] [Full Text] [Related]

  • 7. Plasminogen activator inhibitor-1 in patients with Kawasaki disease: diagnostic value for the prediction of coronary artery lesion and implication for a new mode of therapy.
    Senzaki H, Kobayashi T, Nagasaka H, Nakano H, Kyo S, Yokote Y, Sasakid N.
    Pediatr Res; 2003 Jun 01; 53(6):983-8. PubMed ID: 12621103
    [Abstract] [Full Text] [Related]

  • 8. Elevated levels of matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 during the acute phase of Kawasaki disease.
    Chua PK, Melish ME, Yu Q, Yanagihara R, Yamamoto KS, Nerurkar VR.
    Clin Diagn Lab Immunol; 2003 Mar 01; 10(2):308-14. PubMed ID: 12626459
    [Abstract] [Full Text] [Related]

  • 9. Tissue inhibitor of metalloproteinase 2 and coronary artery lesions in Kawasaki disease.
    Furuno K, Takada H, Yamamoto K, Ikeda K, Ohno T, Khajoee V, Mizuno Y, Hara T.
    J Pediatr; 2007 Aug 01; 151(2):155-60, 160.e1. PubMed ID: 17643768
    [Abstract] [Full Text] [Related]

  • 10. Increased serum levels of vascular endothelial growth factor in Kawasaki disease.
    Maeno N, Takei S, Masuda K, Akaike H, Matsuo K, Kitajima I, Maruyama I, Miyata K.
    Pediatr Res; 1998 Oct 01; 44(4):596-9. PubMed ID: 9773852
    [Abstract] [Full Text] [Related]

  • 11. [Expression of monocyte chemotactic protein-1 in peripheral blood mononuclear cells of children with Kawasaki disease and its relation to coronary artery impairment].
    Zhang J, Gui YH, Yang Y.
    Zhonghua Er Ke Za Zhi; 2008 Feb 01; 46(2):132-5. PubMed ID: 19099689
    [Abstract] [Full Text] [Related]

  • 12. [Clinical significance of anti-neutrophil cytoplasmic antibodies and anti-endothelial cell antibodies in children with Kawasaki disease].
    Zhao JM, Wang XH.
    Zhongguo Dang Dai Er Ke Za Zhi; 2014 Jul 01; 16(7):740-4. PubMed ID: 25008884
    [Abstract] [Full Text] [Related]

  • 13. [Prediction of the risk of coronary arterial lesions in Kawasaki disease by N-terminal pro-brain natriuretic peptide].
    Huiling L, Yaping L, Xiufen H.
    Zhonghua Er Ke Za Zhi; 2015 Apr 01; 53(4):300-3. PubMed ID: 26182507
    [Abstract] [Full Text] [Related]

  • 14. The pathophysiology of coronary artery aneurysms in Kawasaki disease: role of matrix metalloproteinases.
    Senzaki H.
    Arch Dis Child; 2006 Oct 01; 91(10):847-51. PubMed ID: 16990356
    [Abstract] [Full Text] [Related]

  • 15. Polymorphism of matrix metalloproteinase-3 promoter gene as a risk factor for coronary artery lesions in Kawasaki disease.
    Park JA, Shin KS, Kim YW.
    J Korean Med Sci; 2005 Aug 01; 20(4):607-11. PubMed ID: 16100452
    [Abstract] [Full Text] [Related]

  • 16. Elastolytic matrix metalloproteinases and coronary outcome in children with Kawasaki disease.
    Lau AC, Rosenberg H, Duong TT, McCrindle BW, Yeung RS.
    Pediatr Res; 2007 Jun 01; 61(6):710-5. PubMed ID: 17426658
    [Abstract] [Full Text] [Related]

  • 17. Increased Pentraxin 3 Levels Correlate With IVIG Responsiveness and Coronary Artery Aneurysm Formation in Kawasaki Disease.
    Kitoh T, Ohara T, Muto T, Okumura A, Baba R, Koizumi Y, Yamagishi Y, Mikamo H, Daigo K, Hamakubo T.
    Front Immunol; 2021 Jun 01; 12():624802. PubMed ID: 33912155
    [Abstract] [Full Text] [Related]

  • 18. Matrix metalloproteinase-9 in vascular lesions and endothelial regulation in Kawasaki disease.
    Sakata K, Hamaoka K, Ozawa S, Niboshi A, Yahata T, Fujii M, Hamaoka A, Toiyama K, Nishida M, Itoi T.
    Circ J; 2010 Aug 01; 74(8):1670-5. PubMed ID: 20534943
    [Abstract] [Full Text] [Related]

  • 19. Aberrantly decreased levels of NKG2D expression in children with kawasaki disease.
    Ge X, Li CR, Yang J, Wang GB.
    Scand J Immunol; 2013 May 01; 77(5):389-97. PubMed ID: 23298273
    [Abstract] [Full Text] [Related]

  • 20. Circulating matrix metalloproteinases and their inhibitors in patients with Kawasaki disease.
    Senzaki H, Masutani S, Kobayashi J, Kobayashi T, Nakano H, Nagasaka H, Sasaki N, Asano H, Kyo S, Yokote Y.
    Circulation; 2001 Aug 21; 104(8):860-3. PubMed ID: 11514369
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.